Global Ripple Effects of the U.S. “MFN” Pricing Order

The US Executive Order on Most-Favoured-Nation (MFN) prescription drug pricing has the potential to reshape more than American pricing. By explicitly seeking to align US prices with lower prices in comparable developed countries, it creates a two-way connection between the world’s largest pharmaceutical market and pricing decisions made elsewhere.

The precise mechanics still require implementation, but pricing teams cannot wait for every detail before considering the strategic implications.

1. Basket uncertainty, but a clear lowest-price direction

A central uncertainty is which countries, products and price concepts will ultimately be used to operationalise MFN targets. Public list prices, estimated net prices and direct manufacturer prices can produce very different benchmarks.

Even with those uncertainties, the policy direction matters: a low price in another developed market could potentially influence the commercial environment in the US. That changes the traditional assumption that smaller ex-US markets can be priced largely on their own economics.

2. Launch sequencing becomes even more strategic

International Reference Pricing already makes launch order important. MFN logic can amplify that effect. An early low-priced launch in a referenced market could create consequences for subsequent US strategy, while delaying launches to protect a global price corridor creates its own patient-access and commercial risks.

Companies therefore need launch-sequence models that can test both conventional IRP cascades and the possibility of US linkage to international benchmarks.

3. Pressure on list-versus-net structures

Many markets maintain relatively high public list prices while negotiating substantial confidential discounts. If an MFN system relies on observable list prices, the impact will differ greatly from a system that attempts to infer or access net transaction prices.

This makes contracting architecture a strategic issue. Manufacturers will need to understand which concessions remain confidential, which prices become visible, and how different interpretations of “price” could feed into US calculations.

4. Potential spill-over into payer negotiations

Even before a formal formula is fully implemented, payers outside the US may use the policy debate as negotiating leverage. If manufacturers argue that low ex-US prices threaten US economics, payers may respond by scrutinising launch timing, confidential discounts and the gap between list and net prices more closely.

What should global teams do now?

Scenario planning is essential. At minimum, global models should identify markets capable of setting the lowest relevant benchmark, test alternative basket definitions, distinguish list and net-price effects, and evaluate the consequences of launch delays or price changes across the full portfolio.

MFN is therefore not only a US market-access issue. It is a global pricing and IRP issue that could alter how companies think about the value of every visible price around the world.

This article reflects the market and policy context at the date of publication.

Further reading

• Executive Order 14297 — The White House